Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEANIC-AF: Asundexian vs apixaban for prevention of stroke/systemic embolism in atrial fibrillation
jRCT2061220080Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of asundexian in Atrial fibrillation (AFib), stroke and systemic embolism (2 arms), sponsored by Bayer. Primary endpoints: Time to first occurrence of composite of stroke or systemic embolism, Time to first occurrence of ISTH major bleeding and 1 more. Started Dec 2022; status: completed.
02
Drugs
asundexian
03
Conditions
Atrial fibrillation (AFib)strokesystemic embolism
Beyond the preview
Go deeper on jRCT2061220080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220080.